Taysha Gene Therapies Inc Total Assets
Taysha Gene Therapies Inc total assets. Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) holds total assets worth $470.43 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TSHA operating cash flow for how efficiently the company converts equity into cash flow.
Total Assets of Taysha Gene Therapies Inc (2019–2025)
Total assets of Taysha Gene Therapies Inc from 2019 to 2025. This chart illustrates how Taysha Gene Therapies Inc's total assets have evolved over time, based on quarterly financial data. See TSHA stock price and chart for real-time trading data and today's change.
Taysha Gene Therapies Inc - Asset Composition Analysis
Taysha Gene Therapies Inc Total Assets Breakdown (December 2025)
Taysha Gene Therapies Inc total assets breakdown as of December 2025. Taysha Gene Therapies Inc's total assets of $470.43 Million consist of 94.6% current assets and 5.4% non-current assets. Explore TSHA working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Taysha Gene Therapies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Taysha Gene Therapies Inc's current assets represent 94.6% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 93.1% of total assets in 2025, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Taysha Gene Therapies Inc Competitors by Total Assets
Key competitors of Taysha Gene Therapies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Taysha Gene Therapies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.76 | 12.48 | 4.56 |
| Quick Ratio | 17.76 | 12.48 | 4.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $435.46 Million | $290.92 Million | $153.96 Million |
Taysha Gene Therapies Inc - Advanced Valuation Insights
This section examines the relationship between Taysha Gene Therapies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.34 |
| Latest Market Cap to Assets Ratio | 4.01 |
| Asset Growth Rate (YoY) | 114.1% |
| Total Assets | $343.32 Million |
| Market Capitalization | $1.38 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Taysha Gene Therapies Inc's assets at a significant premium (4.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Taysha Gene Therapies Inc's assets grew by 114.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Taysha Gene Therapies Inc (2019–2025)
The table below shows the annual total assets of Taysha Gene Therapies Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $343.32 Million | +114.09% |
| 2024-12-31 | $160.36 Million | -7.16% |
| 2023-12-31 | $172.73 Million | +36.79% |
| 2022-12-31 | $126.28 Million | -40.98% |
| 2021-12-31 | $213.96 Million | -17.35% |
| 2020-12-31 | $258.88 Million | +1725773.33% |
| 2019-12-31 | $15.00K | -- |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 … Read more